Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currency Instruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regions Pharma grew 10% in…
